Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Trastuzumab deruxtecan (T-DXd) with pyrotinib
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences